Approved indications: Tagrisso is FDA‑approved for adults with: (1) metastatic non‑small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as initial (first‑line) treatment; (2) metastatic EGFR T790M‑positive NSCLC, after progression on or after prior EGFR‑TKI therapy; and (3) as adjuvant treatment after complete tumor resection in patients with EGFR exon 19 deletions or exon 21 L858R mutation–positive NSCLC.

Off‑label uses: Clinicians may occasionally use osimertinib off label for uncommon EGFR mutations or in other lines or combinations in NSCLC when clinical trial data or small studies suggest benefit, but the strength of evidence is generally lower than for its approved uses and varies by mutation and setting.

Efficacy expectations: Many patients experience tumor shrinkage or disease control, often within the first 6 to 12 weeks of therapy, with median progression‑free survival in key trials generally longer than with earlier‑generation EGFR inhibitors in similar populations. In EGFR‑mutated metastatic NSCLC, Tagrisso has shown improved progression‑free survival and overall survival compared with first‑generation EGFR TKIs, and in the adjuvant setting it significantly reduces the risk of disease recurrence versus placebo.

Typical dosing: The usual adult dose is 80 mg by mouth once daily for metastatic EGFR‑mutated NSCLC or as adjuvant therapy after resection, continued until disease progression, unacceptable toxicity, or completion of the planned adjuvant course. Pediatric use is not routine and would be specialist‑directed if considered.

How to take: Tagrisso can be taken with or without food, at about the same time each day. Tablets should be swallowed whole; if swallowing is difficult, they may be dispersed in non‑carbonated water according to instructions from the prescribing information, and the mixture should be taken immediately. Do not crush, chew, or split the tablets.

Special dosing instructions: Dose reductions or temporary interruptions may be needed for significant side effects, heart or lung problems, or lab abnormalities, following a stepwise schedule (for example, from 80 mg to 40 mg once daily) as directed by the oncologist. Therapy may be permanently discontinued for certain serious toxicities such as confirmed severe interstitial lung disease or life‑threatening cardiac events.

Missed dose: If a dose is missed and less than 12 hours have passed, take it as soon as remembered; if more than 12 hours have passed, skip the missed dose and take the next dose at the usual time. Do not take two doses at once to make up for a missed dose.

Overdose: In case of suspected overdose, contact a poison control center or seek emergency medical care immediately; bring the medication container so providers know exactly what was taken. Monitoring may include heart rhythm, vital signs, and supportive care.

Common side effects: Frequently reported effects include diarrhea, rash or dry/itchy skin, stomatitis (mouth sores), nail changes, decreased appetite, fatigue, and cough. These usually appear in the first weeks of treatment and are often mild to moderate, but they can sometimes be bothersome and may require dose adjustments or supportive care.

Serious or rare adverse effects: Tagrisso can cause serious lung problems such as interstitial lung disease or pneumonitis (new or worsening cough, fever, or shortness of breath), heart rhythm changes including QTc prolongation (which can cause palpitations, dizziness, or fainting), decreased heart function (heart failure‑like symptoms such as shortness of breath, swelling, or rapid weight gain), and eye problems or serious skin reactions. Any sudden breathing difficulty, chest pain, severe rash or blistering, vision changes, or fainting requires urgent medical attention.

Warnings and precautions: Tagrisso can harm an unborn baby; effective contraception is recommended during treatment and for a period after the last dose for both patients who can become pregnant and partners. Breastfeeding is not recommended during therapy and for some time after the final dose. Use requires caution and sometimes dose adjustment or closer monitoring in patients with heart disease, history of QT prolongation, electrolyte abnormalities, or significant lung disease; limited data are available in severe kidney or liver impairment. It is not typically used in children; safety and effectiveness are established primarily in adults.

Comparative safety: Compared with earlier EGFR inhibitors, Tagrisso tends to cause fewer severe rash and diarrhea events but may carry greater concern for certain cardiac effects, so heart and rhythm monitoring are particularly important.

Reporting and safety updates: Side effects should be reported to the prescribing clinician and can also be reported directly to the FDA MedWatch program or the drug manufacturer. Patients and clinicians can check FDA drug safety communications and the prescribing information for the most current safety warnings and updates.

Drug and supplement interactions: Strong CYP3A inducers (such as rifampin, carbamazepine, phenytoin, and St. John’s wort) can decrease Tagrisso levels and may reduce effectiveness and are generally avoided. Certain medicines that prolong the QT interval (some antiarrhythmics, antipsychotics, macrolide antibiotics, and fluoroquinolones) can increase the risk of heart rhythm problems when combined. Acid‑reducing agents do not have major known effects on exposure, but all prescription and over‑the‑counter medicines and supplements should be reviewed with the oncology team.

Food, alcohol, and procedures: Tagrisso can be taken without regard to meals, and no specific food restrictions are standard, though maintaining good nutrition and hydration is encouraged. Moderate alcohol intake may be permissible for some patients but should be discussed with the clinician, especially if there are liver, heart, or other comorbid conditions. There are no common contraindications with imaging or diagnostic procedures, but contrast agents and other drugs used during procedures should be reviewed for QT‑prolonging potential.

Precautions and conditions affecting safety: Use requires caution in patients with a history of heart failure, reduced left ventricular ejection fraction, arrhythmias, or congenital long QT syndrome, as well as those with electrolyte disturbances (low potassium, magnesium, or calcium). Patients with prior or existing interstitial lung disease or significant chronic lung disease are at higher risk for serious lung toxicity. Careful review of all co‑medications and comorbid conditions is needed before and during therapy.

Monitoring needs: Routine monitoring typically includes periodic electrocardiograms (ECGs) and electrolytes in patients with cardiac risk factors or on QT‑prolonging drugs, echocardiograms or other assessments of heart function in selected patients, and regular clinical evaluations for respiratory symptoms, skin and gastrointestinal toxicity. Imaging studies are performed at intervals to assess tumor response. Lab tests may also monitor blood counts and organ function as clinically indicated.

Q: How long can I stay on Tagrisso?
A: Most patients continue Tagrisso as long as it is working and side effects are manageable; in metastatic disease this usually means until the cancer clearly progresses or toxicity becomes unacceptable, while in the adjuvant setting it is given for a defined course (commonly up to three years) if tolerated.

Q: When will I know if Tagrisso is working?
A: Many people notice symptom improvement or stable disease within the first couple of months, but the main way to know is through follow‑up scans, which are typically done every few months to look for tumor shrinkage or lack of growth.

Q: Can Tagrisso cure my lung cancer?
A: Tagrisso can significantly delay progression and improve survival, and in the adjuvant setting it reduces the risk of recurrence, but metastatic EGFR‑mutated NSCLC is generally considered treatable rather than curable, and long‑term control varies from person to person.

Q: Is hair loss common with Tagrisso?
A: Unlike many traditional chemotherapies, Tagrisso does not usually cause complete hair loss, though some patients experience hair thinning, changes in hair texture, or slower hair growth along with skin and nail changes.

Q: Do I need to avoid being around others while taking Tagrisso?
A: Tagrisso itself is not contagious, and you do not pose a medication risk to people around you, but because cancer and its treatments can affect your overall health, your care team may recommend vaccines, infection‑prevention measures, and reasonable precautions based on your blood counts and general condition.

Storage: Store Tagrisso tablets at room temperature (generally 68°F to 77°F / 20°C to 25°C), in the original container, tightly closed, away from moisture and excess heat, and out of reach of children and pets.

Disposal: Do not flush unused tablets down the toilet or throw them in household trash; instead, use a medicine take‑back program or follow pharmacist or local waste guidelines for disposing of unused cancer medicines.